Status:
COMPLETED
Integrin α6-targeted SPECT Imaging of Breast Cancer
Lead Sponsor:
Peking University
Collaborating Sponsors:
China-Japan Union Hospital, Jilin University
Sun Yat-sen University
Conditions:
Breast Cancer
Eligibility:
All Genders
25-60 years
Phase:
EARLY_PHASE1
Brief Summary
A novel radiotracer 99mTc-RWY targeting Integrin α6 was developed, and the pilot first-in-human study for SPECT imaging of breast cancer was performed in seven healthy volunteers and two breast cancer...
Detailed Description
Integrin α6 associates with the survival and migration of breast cancer cells, which emerges as a predictor of reduced overall survival and worse prognosis. In this study, we developed an integrin α6-...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Healthy volunteers.
- Body mass index (BMI) at 19 to 25 \[Body mass index = body weight (kg)/ height squared (m2)\];
- Clinical laboratory tests (heart, liver, kidney, blood) indicators are in the normal range or abnormalities without clinical significance;
- Informed written consents were obtained from all 9 subjects before the procedure.
- Patients in suspicion of breast cancer by mammography or ultrasonography, and being able to provide basic information.
- Exclution Criteria:
- • The investigator judged that it is not suitable for clinical trials based on the overall situation of the volunteers and patients.
Exclusion
Key Trial Info
Start Date :
March 8 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2019
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT04289532
Start Date
March 8 2018
End Date
June 30 2019
Last Update
March 6 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Health Science Center
Beijing, Beijing Municipality, China